CompanyCRDLNasdaqOakville, A6

Cardiol Therapeutics Inc.

Cardiol Therapeutics develops CardiolRx, a small-molecule inflammasome pathway modulator for heart disease.

SEC EDGAR ClinicalTrials.gov cardiolrx.com

SCHEDULE 13G/ASep 23Latest SEC filing

Sep 23Latest story

September 2026

Cardiol hits MAVERIC enrollment target early, expands trial to 150 patients

Sep 23Clinical readoutCardiol Therapeutics Inc.

August 2026

Cardior posts Phase 2 HF-REVERT results for CDR132L in post-MI heart failure

Aug 26Trial updateCardiol Therapeutics Inc.CDR132L

July 2026

Cardiol's Phase II pericarditis data published in JAHA as Phase III MAVERIC nears full enrollment

Jul 14Clinical readoutCardiol Therapeutics Inc.pharmaceutically produced cannabidiol